Table 1. . Meningioma patient treatment characteristics.
| Patient number | Sex/age (years) | Location | Initial therapy | Salvage therapy | IFN-α therapy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | RT (Gy) | SRS (Gy) | Surgery | RT (Gy) | SRS (Gy) | Chemotherapy (cycles) | Cycles (n) | Response | PFS (weeks) | |||||
| 1†‡ | F/86 | L frontal | GTR | 60 | No | No | No | 15 | HU (1) | 1 | PD | 4 | ||
| 2† | M/75 | R frontal | STR | 59.4 | No | STR | No | 14 | HU (1) | 2 | PD | 8 | ||
| 3† | F/70 | R cavernous sinus, R sphenoid | STR | 54 | No | STR | No | 12 | HU (1) | 6 | SD | 26 | ||
| 4†‡ | F/68 | L frontal | GTR | 60 | No | STR | No | 14 | HU (1) | 4 | SD | 16 | ||
| 5 | F/63 | L and R parietal | STR | 54 | No | STR | No | 15 | HU (1) Sandostatin® LAR (3) | 13 | SD | 52 | ||
| 6‡ | F/72 | L sphenoid, L cavernous sinus | STR | 60 | No | Biopsy | No | 12 | HU (1) | 3 | SD | 12 | ||
| 7† | F/56 | R parietal | GTR | 60 | No | STR | No | 15 | HU (1) | 2 | PD | 8 | ||
| 8†‡ | M/42 | R temporal, R frontal | STR | 60 | No | STR × 2 | No | 14 | HU (1) | 3 | PD | 12 | ||
| 9† | F/61 | L tentorium, L cerebello-pontine angle | GTR | 60 | No | STR | No | 14 | HU (1) | 5 | SD | 20 | ||
| 10‡ | M/36 | Bifrontal | STR | 60 | No | No | No | 14 | HU (3) | 2 | PD | 8 | ||
| 11 | F/63 | L parietal, R parietal, L occipital | STR | 54 | No | STR | No | 15 | HU (2) | 3 | PD | 12 | ||
| 12† | F/80 | R frontal | GTR | 60 | No | STR | No | 14 | HU (1.5) | 2 | PD | 8 | ||
| 13† | M/52 | L frontal | GTR | 59.4 | No | GTR | No | 15 | HU (1.5) | 7 | SD | 28 | ||
| 14†‡ | F/66 | R frontal, R parietal | STR | 60 | No | STR | No | 16 | HU (1.5) | 3 | PD | 12 | ||
| 15 | F/82 | L sphenoid, L pterygo-palatine fossa, L cavernous sinus | STR | 60 | No | No | No | 12 | HU (2) | 5 | SD | 20 | ||
| 16† | F/67 | L temporal | GTR | 60 | No | STR | No | 15 | HU (1.5) | 6 | SD | 24 | ||
| 17†‡ | M/68 | R cavernous sinus | Biopsy | 60 | No | No | No | 12 | HU (2) | 4 | SD | 16 | ||
| 18† | M/51 | R frontal, R parietal | STR | 59.4 | No | STR × 2 | No | 15 | HU (2) | 7 | SD | 28 | ||
| 19† | F/78 | R frontal | GTR | 60 | No | No | No | 12 | HU (2) | 2 | PD | 8 | ||
| 20†‡ | F/63 | L occipital | GTR | 60 | No | STR | No | 14 | HU (2) | 3 | SD | 12 | ||
| 21† | F/69 | R frontal | GTR | 59.4 | No | GTR | No | 15 | HU (2) | 5 | SD | 20 | ||
| 22† | F/66 | L frontal, R frontal | STR | 60 | No | No | No | 14 | HU (2) | 6 | SD | 24 | ||
| 23†‡ | F/40 | R parietal | GTR | 60 | No | No | No | 18 | HU (2.5) | 8 | SD | 32 | ||
| 24† | F/66 | R tentorium | GTR | 59.4 | No | STR | No | 14 | HU (2.5) | 1 | PD | 4 | ||
| 25† | F/62 | R cavernous sinus | Biopsy | 60 | No | No | No | 14 | HU (3) | 5 | SD | 20 | ||
| 26†‡ | F/48 | R frontal | GTR | 60 | No | STR | No | 14 | HU (3) | 11 | SD | 44 | ||
| 27† | M/66 | R parietal | STR | 59.4 | No | No | No | 18 | HU (3) | 1 | PD | 4 | ||
| 28†‡ | F/60 | L fontal, L parietal | Biopsy | 60 | No | No | No | 14 | HU (3.5) | 4 | SD | 16 | ||
| 29† | F/76 | L and R frontal | STR | 59.4 | No | No | No | 12 | HU (3.5) | 1 | PD | 4 | ||
| 30† | F/79 | R frontal | GTR | 60 | No | No | No | 15 | HU (4) | 2 | PD | 8 | ||
| 31† | F/70 | R frontal | GTR | 59.4 | No | GTR | No | 15 | HU (4.5) | 2 | PD | 8 | ||
| 32†‡ | F/38 | R cavernous sinus | Biopsy | 59.4 | No | No | No | 15 | HU (15) | 8 | SD | 32 | ||
| 33† | F/82 | R temporal, falx, R sphenoid | STR | 60 | No | STR | No | 14 | HU (5) | 1 | PD | 4 | ||
| 34†‡ | F/62 | L cavernous sinus, L sphenoid | STR | 59.4 | No | No | No | 14 | HU (6) | 5 | SD | 20 | ||
| 35† | F/67 | L and R frontal | STR | 54 | No | STR | No | 12 | HU (7) | 2 | PD | 8 | ||
†Previously reported in part [12,16].
‡WHO grade 3 meningioma.
F: Female; GTR: Gross total resection; HU: Hydroxyurea; L: Left; M: Male; PD: Progressive disease; PFS: Progression-free survival; R: Right; RT: External-beam radiotherapy; SD: Stable disease; SRS: Stereotactic radiosurgery; STR: Subtotal resection.